Shortages of cancer medicines can delay or interrupt treatment, and many lung cancer medicines cannot easily be replaced when supplies run low.

The EU Critical Medicines Act aims to make medicine supplies across Europe stronger and more reliable. This fact sheet explains what the Act could mean for lung cancer treatment, where it could improve access and the important gaps it does not yet address.